10x Genomics Q2 revenue $151M (+3% ex-settlements); raises FY2026 guidance to $610-630M

10x Genomics, Inc.

Revenue $151.0M, up 3% YoY excluding patent settlement revenue; gross margin 74% vs 72%.
Operating loss $19.6M vs prior-year operating income $30.1M; net loss $17.9M vs net income $34.5M.
Acquired Proteintech Genomics for protein detection; collaborations with Cleveland Clinic and Lausanne University Hospital.
Raises FY2026 revenue guidance to $610-630M from $600-625M, representing 2-5% growth ex-settlements.
Cash and marketable securities $552.0M as of June 30, 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.